Results 111 to 120 of about 181,905 (281)

South African Propolis: Anti‐Helicobacter pylori Activity, Chemistry, and Toxicity

Chemistry &Biodiversity, EarlyView.
ABSTRACT Propolis, a resin‐like substance produced by bees, has previously shown antimicrobial activity against the ulcer‐causing gut pathogen Helicobacter pylori. South African propolis, however, was yet to be investigated. This study aimed to investigate a comprehensive range of South African propolis for its antimicrobial activity against H.
Sarhana Dinat, Ané Orchard, Efficient Ncube, Weiyang Chen, Alvaro Viljoen, Sandy van Vuuren   +5 more
wiley   +1 more source

Ethnomedicinal Uses, Phytochemistry, Pharmacological Activities, and Toxicology of the Subfamily Gomphrenoideae (Amaranthaceae): A Comprehensive Review

Chemistry &Biodiversity, EarlyView.
ABSTRACT The subfamily Gomphrenoideae is composed of about 480 accepted species, many of which have been historically used as medicinal plants, reason why they have been studied in terms of chemical profile, biological activity, and safety. This review consolidates the advances in research on this subfamily over the past 47 years, emphasizing its ...
Dayanna Isabel Araque Gelves, Giulia Cristina de Andreoli Souza, Alvaro Jose Hernandez Tasco, Marcos José Salvador   +3 more
wiley   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

Waxy‐ or Putty‐Like Materials as a Novel Drug Preparation for Synthetic Cannabinoid Receptor Agonists: Detection in Prisons and In Vitro Cannabinoid Receptor Activity

Drug Testing and Analysis, EarlyView.
Waxy‐ or putty‐like materials has emerged as a novel drug preparation for synthetic cannabinoids and other drugs in UK prisons. An in vitro CB1 bioassay was used to evaluate the CB1 activating potential of MDMB‐INACA and extracts from eight seized samples. MDMB‐INACA had moderate efficacy but low potency at CB1.
Axelle Timmerman, Marie H. Deventer, Rachael Andrews, Robert Reid, Victoria Marland, Darren Edwards, Christopher R. Pudney, Niamh Nic Daéid, Christophe P. Stove, Caitlyn Norman   +9 more
wiley   +1 more source

Annual Banned‐Substance Review 17th Edition—Analytical Approaches in Human Sports Drug Testing 2023/2024

Drug Testing and Analysis, EarlyView.
Scenarios of drug exposure and administration as well as detection assays for drugs and methods of sports doping published between 2023 and 2024 are critically reviewed and evaluated in context with the Prohibited List 2024 as established by the World Anti‐Doping Agency.
Mario  Thevis, Tiia  Kuuranne, Hans  Geyer   +2 more
wiley   +1 more source

Identification and Investigation of the Intrinsic Receptor Activation Potential and Metabolization of the New Oxo‐Pyridyl Synthetic Cannabinoid Receptor Agonist CH‐FUBBMPDORA

Drug Testing and Analysis, EarlyView.
Another Chinese generic ban‐evading SCRA, CH‐FUBBMPDORA, has emerged. This study reports its first identification in Europe, its analytical characterization (NMR, Raman, FTIR, GC–MS, and HRMS), its cannabinoid activation potential in a βarr2 recruitment assay, and its metabolization profile.
Marie H. Deventer, Maria Carmela Emanuele, Brianna N. Stang, Katleen Van Uytfanghe, Jessica Masson, Xavier Bouvot, Catherine Lamoureux, Alessandro Proposito, Fabiano Reniero, Margaret V. Holland, Alex J. Krotulski, Luisa Mannina, Christophe P. Stove, Claude Guillou   +13 more
wiley   +1 more source

Cost‐utility analysis of add‐on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China

ESC Heart Failure, EarlyView.
Abstract Aims The study aimed to analyse the cost‐utility of Chinese patent medicine Qili Qiangxin (QLQX) capsules in heart failure with a reduced ejection fraction from the healthcare payer's perspective. Methods and results From the perspective of the healthcare payer, a Markov model was established to estimate the cost‐utility of adding QLQX ...
Lu Wang, Yinglin Wang, Quan Zhao
wiley   +1 more source

Divergent Total Syntheses of 7,20‐Epoxy, 3,20‐Epoxy, and 6,7‐seco‐ent‐Kaurane Diterpenoids

European Journal of Organic Chemistry, EarlyView.
A concise and versatile synthesis of 7,20‐epoxy‐ent‐kaurane diterpenoids is developed and its tetracyclic core is converted divergently to the skeletons of 3,20‐epoxy and 6,7‐seco‐ent‐kaurane diterpenoids via a bioinspired strategy. Collectively nine total syntheses are achieved.
Bo Wang, Wenjing Ma, Andrew‐Go Zhuang, Han Luo, Lizhi Zhu, Wei Han, Chi‐Sing Lee   +6 more
wiley   +1 more source

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol

Exploration, EarlyView.
Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu, Guiyu Dai, Yanyan Chen, Lihua Tan, Hanqing Liu, Meiwan Chen   +5 more
wiley   +1 more source